NCT01647659View on ClinicalTrials.gov

Relative Bioavailibilty for Pediatric Powder for Suspension (PfOS) Formulation

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

July 30, 2012

Primary Completion Date

November 12, 2012

Study Completion Date

November 12, 2012

Conditions
Cancer
Interventions
DRUG

Trametinib tablet

2 mg, orally, on Day 1 of the dosing period

DRUG

Trametinib pediatric formulation

2 mg, orally, on Day 1 of the dosing period

Trial Locations (2)

37203

GSK Investigational Site, Nashville

85259

GSK Investigational Site, Scottsdale

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY